Search for stocks /

Sanstar Ltd Q1 FY26 – Maize Magic, 45% CAGR Hangover & a Starchy IPO Recipe πŸŒ½πŸ“‰


1. At a Glance

Sanstar Ltd, India’s third-largest maize-based specialty products maker, just dropped a masala-movie style Q1 FY26: Revenue β‚Ή169 Cr (-44% YoY), PAT negative β‚Ή0.33 Cr (-102%). From 45% CAGR (FY22–FY24) to Q1 nosedive, the contrast is sharper than switching from Sholay to Student of the Year. Stock trades at β‚Ή95 (P/E 64.5!), with ROE just 9.6%. Basically, the starch hero slipped on its own corn syrup.


2. Introduction

Picture this: you’re at a Gujarati wedding, and every food item on your plate β€” from halwa to pani puri stuffing β€” has hidden starch. That’s Sanstar’s invisible empire. They take maize, grind it into starches, syrups, sorbitol, and glucose, then sneak it into your daily food, pet food, cosmetics, and pharma products.

Between FY22–FY24, Sanstar’s revenues soared at 45% CAGR, the kind of growth that makes PE investors drool like kids in a candy shop. They even built a giant facility at Dhule (7.9 msf land, 247,500 TPA capacity) and another USFDA-registered plant at Kutch. The future was looking like a Bollywood interval fight scene β€” unstoppable.

And then FY25–26 came along with the twist. Sales slowed, margins shrank, profits tumbled. In Q1 FY26, OPM slipped into -1% territory. Imagine running the third-largest maize processor in India and still managing to lose money in a country where even popcorn at multiplex has 90% margin. Respect.


3. Business Model – WTF Do They Even Do?

Sanstar’s job is simple: turn maize into everything except popcorn.

  • Food ingredients (58% revenue): starches, glucose, sweeteners, emulsifiers. Without them, ketchup won’t flow, Maggi won’t bind, and dairy desserts would collapse faster than a politician’s promise.
  • Animal nutrition (10.5%): maize gluten, germ, and co-products to fatten cows, chickens, and probably half of Instagram fitness influencers.
  • Industrial & pharma uses (31.5%): disintegrants, excipients, binders. Basically, the glue holding pharma pills and industrial coatings together.

Product basket: maize starch (63% share), derivatives (16.5%), co-products (6.5%), others (14%). If you’ve ever licked a lollipop, eaten HUL ketchup, or taken Zydus supplements, chances are you’ve licked Sanstar’s margins too.

Client list? Fancy names like ITC, HUL, Godrej Agrovet, AB Mauri, and Zydus Wellness. Over 525 customers in FY24, with 96 repeat customers who return loyally like Salman Khan’s fans at Eid.

But here’s the rub: global starch market is a commodity circus. Prices depend on maize supply, sugar alternatives, and global demand cycles. You can’t brand β€œmodified starch” like you brand Maggi. Sanstar is stuck selling invisible ingredients, so margins often look anorexic.


4. Financials Overview

MetricLatest Qtr (Q1 FY26)YoY Qtr (Q1 FY25)Prev Qtr (Q4 FY25)YoY %QoQ %
Revenueβ‚Ή169 Crβ‚Ή303 Crβ‚Ή226 Cr-44.2%-25.2%
Join 10,000+ investors who read this every week.
Become a member
error: Content is protected !!